Skip to main content
Terug
Watch Compare

ELITE PHARMACEUTICALS INC /NV/

Datakwaliteit: 100%
ELTP
OTC Manufacturing Chemicals
€ 0,38
€ 0,00 (0,00%)
6 months return
—
Momentum
Neutral
5Y revenue growth
34,90%

Groei

Revenue Growth (5Y)
34,90%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)48,42%
Earnings (1Y)-121,46%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
61,18%
Boven sectorgemiddelde (-54,47%)
ROIC35,81%
Net Margin30,98%
Op. Margin35,74%

Veiligheid

Debt / Equity
N/A
Current Ratio7,34
Interest Coverage440,71

Waardering

PE (TTM)
9,43
Boven sectorgemiddelde (-1,49)
P/B Ratio5,10
EV/EBITDA7,99
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue grew 34,90% annually over 5 years — strong growth
Earnings declined -121,46% over the past year
ROE of 61,18% indicates high profitability
Net margin of 30,98% shows strong profitability
Generating 17,24 M in free cash flow
P/E of 9,43 — trading at a low valuation

Price History

Financiële Trends

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstverassingen

EPS
Reported Estimate
Q22010 Q32010 Q42010
Reported -€ 0,05 € 0,01 € 0,02
Estimate — — —
Verrassing — — —

Growth

Rev 5Y: 34,90% · Earnings 1Y: -121,46%
Revenue Growth (1Y) 48,42% Revenue Growth (3Y) 56,86%
Earnings Growth (1Y) -121,46% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 34,90% Earnings Growth (5Y) N/A

Profitability

ROE: 61,18% · Net Margin: 30,98%
Revenue (TTM) 140,12 M Net Income (TTM) 43,41 M
ROE 61,18% ROA 35,63%
Gross Margin 51,06% Operating Margin 35,74%
Net Margin 30,98% Free Cash Flow (TTM) 17,24 M
ROIC 35,81% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 7,34
Debt / Equity N/A Current Ratio 7,34
Interest Coverage 440,71 Asset Turnover 1,15
Working Capital 83,60 M Tangible Book Value 74,68 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: 9,43 · EV/EBITDA: 7,99
P/E Ratio 9,43 Forward P/E N/A
P/B Ratio 5,10 P/S Ratio 2,92
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 7,99 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 4,21%
Market Cap 409,26 M Enterprise Value 409,26 M

Per Share

EPS: 0,04 · FCF/Share: 0,02
EPS (Diluted TTM) 0,04 Revenue / Share 0,13
FCF / Share 0,02 OCF / Share 0,02
EPS CAGR (1Y) -100,00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 39,71% · CapEx/Rev: 0,91%
CapEx / Revenue 0,91% FCF Conversion 39,71%
SBC-Adj. FCF N/A Growth Momentum 13,52

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 84,04 M 56,63 M 34,16 M 32,26 M 25,38 M
Net Income -4,31 M 20,11 M 3,56 M 8,90 M 5,09 M
EPS (Diluted) 0,00 0,02 0,00 0,01 0,01
Gross Profit 40,09 M 26,36 M 16,59 M 14,80 M 11,87 M
Operating Income 19,60 M 10,79 M 3,68 M 5,07 M 2,10 M
EBITDA — — — — —
R&D Expenses 7,96 M 6,88 M 6,20 M 4,05 M 5,11 M
SG&A Expenses — — — — —
D&A 1,23 M 1,32 M 1,28 M 1,21 M 1,31 M
Interest Expense 128.234,0 588.622,0 1,11 M 191.816,0 259.598,0
Income Tax 4,26 M -19,65 M 424.028,0 -1,74 M —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 96,39 M 83,65 M 40,90 M 35,15 M 26,19 M
Total Liabilities 42,87 M 26,07 M 11,94 M 9,93 M 10,04 M
Shareholders' Equity 53,52 M 57,58 M 28,96 M 25,22 M 16,15 M
Total Debt — — — 1,36 M 1,47 M
Cash & Equivalents — 7,11 M 7,83 M 8,54 M 3,19 M
Current Assets 57,74 M 40,01 M 21,51 M 18,86 M 12,19 M
Current Liabilities 11,84 M 13,05 M 7,83 M 6,69 M 5,81 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E 9,4 -1,5
P/B 5,1 1,6
ROE % 61,2 -54,5
Net Margin % 31,0 -41,5
Rev Growth 5Y % 34,9 1,8
D/E — 0,3

Strategiescores

1 strategy matched
Growth Capital Light Compounder
#11 of 85
52

Recente Activiteit

Ingestapt Capital Light Compounder
Apr 12, 2026